Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it has granted equity inducement awards to 17 new non-executive employees under the company’s 2025 Inducement Plan.
Madrigal Pharmaceuticals Grants Equity Awards to New Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it will present at the Morgan Stanley 23rd Annual Global Health Care Conference on Monday, September 8, 2025, at 7:45 a.m. …
Madrigal Pharmaceuticals to Present at Morgan Stanley Global Health Care Conference Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it has granted equity inducement awards to 11 new non-executive employees as part of its 2025 Inducement Plan. The awards, approved …
Madrigal Pharmaceuticals Grants Equity Awards to New Employees Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced that the European Commission (EC) has granted conditional marketing authorization for Rezdiffra (resmetirom), marking the first approved treatment in the …
Madrigal Pharmaceuticals Secures EU Approval for First-Ever MASH Therapy Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 10:30 a.m. EDT.
Madrigal Pharmaceuticals to Present at Canaccord Genuity Growth Conference Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it has granted equity awards to 26 newly hired non-executive employees as part of its 2025 Inducement Plan. The awards, approved …
Madrigal Pharmaceuticals Grants Equity Awards to New Hires Under Inducement Plan Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported strong second-quarter results, led by surging demand for Rezdiffra™, its recently launched treatment for metabolic dysfunction-associated steatohepatitis (MASH). The company also outlined …
Madrigal Reports $212.8M in Q2 Rezdiffra Sales, Expands Global Pipeline and Secures $500M Financing Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) announced Monday it has secured exclusive global rights to develop and commercialize SYH2086, a preclinical oral GLP-1 receptor agonist, through a licensing deal with …
Madrigal Licenses Oral GLP-1 Drug From CSPC, Targets Next-Gen MASH Therapy Read MoreCONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will announce its Q2 2025 financial results on Wednesday, Aug. 5, 2025, before U.S. markets open.
Madrigal Pharmaceuticals to Announce Q2 2025 Results with Live Webcast Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has secured a $500 million senior secured credit facility from funds managed by Blue Owl Capital (NYSE: OWL), strengthening its financial position …
Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline Read More